<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03418480</url>
  </required_header>
  <id_info>
    <org_study_id>RHMCAN0983</org_study_id>
    <secondary_id>2014-002061-30</secondary_id>
    <secondary_id>ISRCTN51789191</secondary_id>
    <nct_id>NCT03418480</nct_id>
  </id_info>
  <brief_title>HPV Anti-CD40 RNA Vaccine</brief_title>
  <acronym>HARE-40</acronym>
  <official_title>Therapeutic HPV Vaccine Trial +/- Anti-CD40 in HPV-driven Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southampton</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioNTech SE</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southampton</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HARE-40 is a phase I/II vaccine dose escalation study with two different arms: Arm 1A will&#xD;
      perform intrapatient dose escalation in patients with previously treated HPV16+ Head &amp; Neck&#xD;
      Cancer using two dose cohorts to establish a safe, tolerable and recommended dose of HPV&#xD;
      vaccine.&#xD;
&#xD;
      Arm 1B will perform intrapatient dose escalation in patients with advanced HPV16+ cancer&#xD;
      (head and neck, anogenital, penile or cervical) using a single cohort to establish a safe,&#xD;
      tolerable and recommended dose of HPV vaccine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 11, 2017</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT) according to CTCAE version 4.03 (Arm 1A)</measure>
    <time_frame>3 months</time_frame>
    <description>Safe and tolerable dose of clinically disease free patients (Arm 1A) - Determination of a suitable dose of HPV RNA</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Carcinoma, Squamous Cell</condition>
  <condition>Head and Neck Neoplasm</condition>
  <condition>Cervical Neoplasm</condition>
  <condition>Penile Neoplasms Malignant</condition>
  <arm_group>
    <arm_group_label>RNA Vaccine A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1A: 15 (6+9) patients with previously treated HPV16+ head and neck squamous cell carcinoma receiving increasing doses of HPV vaccine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RAN Vaccine B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1B: 29 (15+14) patients with HPV16+ advanced disease receiving increasing doses of HPV vaccine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HPV vaccine</intervention_name>
    <description>Intradermal vaccine</description>
    <arm_group_label>RAN Vaccine B</arm_group_label>
    <arm_group_label>RNA Vaccine A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Arm 1A:&#xD;
&#xD;
          -  Previous HPV16+ head and neck squamous cell carcinoma.&#xD;
&#xD;
          -  At least 12 months after completion of treatment.&#xD;
&#xD;
          -  Within 5 years of treatment completion.&#xD;
&#xD;
          -  Currently no clinical evidence of disease.&#xD;
&#xD;
          -  ECOG performance status 0 or 1.&#xD;
&#xD;
        Arm 1B:&#xD;
&#xD;
          -  HPV16+ head and neck, cervical, anogenital and penile carcinoma patients with&#xD;
             recurrent disease.&#xD;
&#xD;
          -  Intention to treat is palliative.&#xD;
&#xD;
          -  Patient willing to have repeated tumour biopsies and re-biopsy deemed safe and&#xD;
             feasible clinically.&#xD;
&#xD;
          -  Tissue samples available confirming HPV16+ disease to send to Central Laboratory.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unable to consent.&#xD;
&#xD;
          -  Any patient who has been previously vaccinated in any Arm of the trial.&#xD;
&#xD;
          -  &lt;18 years&#xD;
&#xD;
          -  Systemic steroids (prednisolone &gt;10 mg/day or equivalent) or other drugs with a likely&#xD;
             effect on immune competence are forbidden during the trial. The predictable need of&#xD;
             their use will preclude the patient from trial entry. Replacement steroids for adrenal&#xD;
             insufficiency/failure are allowed.&#xD;
&#xD;
          -  Major surgery in the preceding three to four weeks, which the patient has not yet&#xD;
             recovered from.&#xD;
&#xD;
          -  Patients who are of high medical risk because of non-malignant systemic disease, as&#xD;
             well as those with active uncontrolled infection.&#xD;
&#xD;
          -  Patients with clinically relevant autoimmune disease will be excluded.&#xD;
&#xD;
          -  Patient with a history of anaphylactic reactions or severe allergies are excluded.&#xD;
&#xD;
          -  Patients with any other condition which in the Investigator's opinion would not make&#xD;
             the patient a good candidate for the clinical trial, such as concurrent congestive&#xD;
             heart failure or prior history of New York Heart Association (NYHA) class III/IV&#xD;
             cardiac disease.&#xD;
&#xD;
          -  Current malignancies at other sites, with the exception of adequately treated basal or&#xD;
             squamous cell carcinoma of the skin. Cancer survivors, who have undergone potentially&#xD;
             curative therapy for a prior malignancy, have no evidence of that disease for five&#xD;
             years and are deemed at low risk for recurrence, are eligible for the study.&#xD;
&#xD;
          -  Patients who are serologically positive for or are known to suffer from Hepatitis B,&#xD;
             C, Syphilis or HIV. Counselling will be offered to all patients prior to testing.&#xD;
&#xD;
          -  Patients who have a positive pregnancy test or who are breast feeding.&#xD;
&#xD;
          -  Fertile males or females who are unable or unwilling to use an effective method of&#xD;
             birth control (eg. condom with spermicide, diaphragm with spermicide, birth control&#xD;
             pills, injections, patches, intrauterine device, or intrauterine hormone-releasing&#xD;
             system) during study treatment and until 28 days after patients finish the study&#xD;
             treatment.&#xD;
&#xD;
          -  Elevated Liver Function Tests - ALT &gt;3.0 x ULN, AST &gt;3.0 x ULN, Bilirubin &gt;3.0 x ULN.&#xD;
&#xD;
          -  Any other investigational drug within 28 days or 5 half-lives depending on what gives&#xD;
             the longer range before the first treatment of this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Ottensmeier, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Southampton NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ioannis Karydis, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Southampton NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univeristy Hospitals Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 15, 2017</study_first_submitted>
  <study_first_submitted_qc>January 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2018</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Penile Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

